Abbott Q1 2025 earnings

Abbott reported first-quarter sales of 10.36 billion dollars, up 4 percent year over year. Organic sales growth was 6.9 percent, or 8.3 percent excluding COVID-19 testing-related sales. GAAP diluted earnings per share were 0.76 dollars, while adjusted diluted EPS rose 11.2 percent to 1.09 dollars. The company reaffirmed its full-year 2025 guidance.

Margins improved: adjusted gross margin rose 140 basis points to 57.1 percent and adjusted operating margin rose 130 basis points to 21.0 percent. Net earnings were 1.33 billion dollars GAAP, or 1.92 billion dollars adjusted, up 10.9 percent.

Segment performance

Nutrition sales grew 3.8 percent reported and 6.8 percent organically, led by strong adult nutrition demand, particularly for Ensure and Glucerna. Diagnostics sales declined 7.2 percent reported and 4.9 percent organically, largely due to falling COVID-19 test sales, which dropped to 84 million dollars from 204 million last year. Core Laboratory Diagnostics grew 0.9 percent organically.

Established Pharmaceuticals rose 2.7 percent reported and 7.8 percent organically, driven by strong growth in key emerging markets. Medical Devices rose 9.9 percent reported and 12.6 percent organically, led by strong Diabetes Care sales (up 21.6 percent organic), driven by FreeStyle Libre, and solid growth in Structural Heart, Heart Failure, and Electrophysiology segments.

Guidance and dividend

Abbott projects full-year 2025 organic sales growth of 7.5 to 8.5 percent and adjusted EPS of 5.05 to 5.25 dollars. Q2 2025 adjusted EPS is projected at 1.23 to 1.27 dollars. The company declared its 405th consecutive quarterly dividend of 0.59 dollars per share, continuing its 53-year streak of annual dividend increases.

Abbott Launches New Delivery System to Improve Pain Treatment for CRPS Patients

Abbott has introduced a next-generation delivery system for its Proclaim™ Dorsal Root Ganglion (DRG) neurostimulation device, aimed at improving the precision and ease of electrode placement during implantations. The system is specifically designed to treat complex regional pain syndrome (CRPS) Types 1 and 2 of the lower limbs—conditions considered among the most painful in the world.

The Proclaim DRG system targets the dorsal root ganglion, a nerve cluster along the spine responsible for transmitting pain signals. The new delivery system enhances maneuverability and durability, allowing physicians to perform the implant procedure more efficiently and potentially broadening access to this advanced treatment.

Clinical data show significant pain relief for users, with 81% average reduction in pain intensity. The improved design is expected to make the procedure more accessible for physicians and increase patient access to DRG therapy.

Abbott emphasized that DRG stimulation provides better outcomes than traditional spinal cord stimulation for CRPS. This advancement underlines Abbott’s continued commitment to refining neuromodulation therapies to help people with chronic pain live fuller lives.

For safety information, visit: [Abbott DRG System Safety](https://bit.ly/3SheU6s).

**Abbott's TriClip™ Shows Sustained Benefits in Treating Leaky Tricuspid Heart Valve**

On March 31, 2025, Abbott announced two-year data from its TRILUMINATE™ Pivotal trial demonstrating that the TriClip™ transcatheter edge-to-edge repair (TEER) system provides significant and sustained improvements for patients with severe tricuspid regurgitation (TR), a condition commonly known as a leaky tricuspid heart valve.

Presented at the American College of Cardiology’s ACC.25 conference and published in *Circulation*, the findings show that TriClip significantly reduced hospitalizations due to heart failure and enhanced patients’ quality of life. TR, if left untreated, can lead to serious complications such as heart failure and even death, especially in patients who are not candidates for open-heart surgery.

Key two-year findings include:
- A significant reduction in heart failure hospitalizations: 0.19 vs. 0.26 events per patient-year in the treatment group versus control (p=0.02).
- 84% of TriClip recipients had reduced TR severity to moderate or less, compared to only 21% in the control group. In crossover patients, this rate improved from 3% to 81% within 30 days.
- Patients receiving TriClip experienced an average 15-point improvement on the Kansas City Cardiomyopathy Questionnaire (KCCQ), which measures symptoms and quality of life. Crossover patients reported a 13-point improvement after receiving the device.

Dr. Saibal Kar, a trial investigator, noted that the results confirmed TriClip’s ability to reduce hospitalizations while sustaining improvements in valve function and quality of life.

Sandra Lesenfants, senior vice president of Abbott’s structural heart business, emphasized that TriClip provides a safe and effective alternative for patients with few treatment options.

TriClip is now approved in over 50 countries, including the U.S., Europe, and Canada. The TRILUMINATE Pivotal trial is the first randomized controlled study comparing TriClip to medical therapy for severe TR.

Abbott Launches Clinical Trial for Coronary IVL System to Improve Treatment of Artery Disease

On March 24, 2025, Abbott announced FDA approval of an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, allowing the company to initiate the TECTONIC clinical trial. The study will evaluate the safety and effectiveness of using sound pressure waves to treat severe calcification in coronary arteries prior to stent placement. Up to 335 patients across 47 U.S. sites will be enrolled.

Coronary artery disease (CAD) affects over 20 million adults in the U.S. and is the leading cause of death nationwide. Traditional interventions can struggle with heavy arterial calcium buildup. Abbott’s investigational IVL system aims to improve outcomes by modifying calcified plaques to optimize stent deployment.

The IVL system builds on Abbott’s broader vascular portfolio, which includes diagnostic and therapeutic tools like optical coherence tomography (OCT) imaging. The company emphasizes its continued commitment to advancing cardiovascular care through new technologies.

Abbott’s Coronary IVL System is currently investigational and not yet commercially available.

Abbott reported strong financial results for the fourth quarter and full-year 2024, with total sales for the year reaching $42.0 billion, a 4.6% increase compared to 2023. Organic sales growth for the underlying base business was 9.6%, excluding COVID-19 testing-related sales. For Q4 2024, sales totaled $11.0 billion, a 7.2% increase, with organic growth excluding COVID-19 tests at 10.1%.

Abbott achieved a full-year GAAP diluted EPS of $7.64 and adjusted EPS of $4.67, with significant contributions from its medical devices and nutrition segments. Key growth drivers included the strong performance of products like FreeStyle Libre® and Ensure®. Abbott also made significant advancements in its R&D pipeline, launching over 15 new products or indications.

For 2025, Abbott forecasts organic sales growth of 7.5% to 8.5%, an adjusted operating margin of 23.5% to 24.0%, and adjusted EPS between $5.05 and $5.25. Additionally, Abbott declared its 404th consecutive quarterly dividend, reflecting its strong commitment to shareholder returns.